Analysts Remain Divided Over DocuSign’s Recent Downsizing Plans
DocuSign, Inc (NASDAQ:DOCU) announced a Board-approved reduction-in-force of roughly 9% of its workforce yesterday. Needham analyst Scott Berg reiterated a Hold on…
Immunovant’s New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
On Wednesday, Immunovant Inc (NASDAQ:IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd’s (NASDAQ:ROIV) Investor Day. IMVT-1402 is a new anti-FcRn monoclonal antibody…
SoFi’s Business Model & Strong Execution Make This Analyst Remain Bullish
After meeting with SoFi Technologies, Inc (NASDAQ:SOFI) CFO at the firm’s Annual Software Summit, Mizuho analyst Dan Dolev reiterated a Buy rating…
Thor Industries’ Demand Slowdown To Affect Revenue & Margins In FY23, Says Analyst
Raymond James analyst Joseph Altobello reiterated an Underperform rating on the shares of Thor Industries Inc (NYSE: THO).
Amazon Analyst Says Website Will Get Pricier: Devices, Prime And This Service Are Reasons Why
Citi analyst Ronald Josey reiterated a Buy rating on Amazon.com Inc (NASDAQ:AMZN) with a $185 price target. Amazon’s refreshed device lineup…
Great News For Alibaba And Peers As HSBC Finds The Sector Promising
HSBC Holdings, plc (NYSE: HSBC) found the outlook of some Chinese industries, from the internet to property, has turned brighter as it had priced in much of the bad news.
Amid Challenging Backdrop, This Analyst Previews Teladoc Health’s Upcoming Q3 Earnings
RBC Capital Markets has cut the price target for Teladoc Health Inc (NYSE:TDOC) from $53 to $35 but reiterates the Outperform rating.…
UiPath Analysts See It Improving Value By Its Platform Strategy
Analysts attended UiPath, Inc's (NYSE: PATH) annual analyst day yesterday.
Morgan Stanley Bets On Boeing’s Prospects Despite Market Pull-Back
Morgan Stanley analyst Kristine T Liwag has reiterated an Overweight rating on the shares of Boeing Co (NYSE:BA) with a price target of…
PepGen’s Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta’s Candidate, Says Analyst
PepGen Inc (NASDAQ:PEPG) reported data from PGN-EDO51’s SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities. SVB notes…